September 12, 2025
Eli Lilly Pauses UK Biotech Incubator Plans Amid Concerns Over NHS Drug Pricing
Eli Lilly; Gateway Labs; UK biotech incubator; pause; investment; NHS drug spending; life sciences; biotech industry; government funding; pharmaceutical innovation
Eli Lilly Loses Appeal to Overturn $183.7 Million Medicaid Rebate Judgment
Eli Lilly; Medicaid; rebate; court ruling; False Claims Act; drug pricing; whistleblower; 7th Circuit Court of Appeals; fraud; $183.7 million judgment
FibroGen Settles with SEC for $1.25M Over Roxadustat Data Tampering Allegations
FibroGen; SEC; roxadustat; data manipulation; settlement; Kin-Hung Peony Yu; phase 3 clinical trial; anemia drug; cardiovascular safety; FDA
Capsida Suspends Gene Therapy Trial After First Patient Death
Capsida Biotherapeutics; gene therapy; CAP-002; clinical trial suspension; STXBP1 encephalopathy; patient death; FDA
AbbVie Extends Rinvoq Exclusivity to 2037, Delaying Generics in U.S.
AbbVie; Rinvoq; patent settlement; generic competition; exclusivity extension; upadacitinib; US market; pharmaceutical litigation